APP and Alzheimer disease: We anticipate   that discovery of drugs that target the translational stalling, RQC and CAT-tailing processes, or those that compensate for the endolysosomal and autophagic defects caused by aberrant APP.C99 may  lead to novel therapeutics for AD and related diseases.